Breaking News

STA Pharmaceutical Sees Rapid Growth in MAH Programs in China

Since the MAH pilot launch, the company has undertaken eight development programs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

STA Pharmaceutical, a China-based global API and drug product CDMO, reports that it has seen a rapid uptake in companies with intent to market their products in China using it as a development and manufacturing partner following the CFDA’s announcement of the new Market Authorization Holder (MAH) pilot program last year in China. The pilot was launched to allow drug license holders to use qualified contract manufacturing service providers in certain geographic areas—10 trial provinces and munici...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters